Massachusetts-based Apnimed, Inc. (Nasdaq: APMD), whose lead oral sleep apnea candidate carries an active FDA new drug application (NDA) and a Q1 2027 decision date, priced an upsized IPO on July 30, 2026, raising USD 192 million in gross proceeds before expenses.
The offering comprised 12 million shares at USD 16.00 per share, with an overallotment option for an additional 1.8 million shares. BofA Securities, Evercore ISI, Cantor, and LifeSci Capital acted as joint book-running managers. Apnimed common stock began trading on the Nasdaq Global Select Market on July 31, 2026, under the ticker APMD, with the offering expected to close on or about August 3, 2026.
The upsized deal reflects demand for a single-asset company whose entire near-term value rests on one regulatory binary. Prior to the IPO, Apnimed had raised approximately USD 284 million through preferred equity and convertible note financings, backed by investors including Shionogi, Columbia Seligman Technology and Information Fund, and Alpha Wave Ventures. In April 2026, the company secured up to USD 150 million in senior secured debt financing from HealthCare Royalty Partners, structured in three tranches tied to closing, FDA approval, and a sales milestone.
Apnimed stated it intends to use the IPO proceeds to support the potential commercial launch of its lead candidate, continue pipeline development including Phase III clinical development of follow-on programs, and for working capital and general corporate purposes.
Apnimed is focused on oral pharmacological therapies for obstructive sleep apnea (OSA), a condition estimated to affect 80 million people in the US and one billion globally, for which no approved pharmacological treatment currently addresses the underlying neuromuscular dysfunction.
Its sole clinical asset is AD109 (Oxnimbi), a once-daily fixed-dose oral combination of aroxybutynin, a novel antimuscarinic, and atomoxetine, a selective norepinephrine reuptake inhibitor (NRI). The combination targets the neuromuscular dysfunction that causes upper airway collapse during sleep. AD109 has completed two Phase III trials — SynAIRgy and LunAIRo — in adults with mild, moderate, and severe OSA, both of which the company reported met their primary endpoints with statistically significant reductions in the apnea-hypopnea index (AHI). The FDA accepted the NDA for AD109 on July 14, 2026, assigning a Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2027.